HOME >> BIOLOGY >> NEWS
Vaccine combined with short-term postexposure antibiotics protects monkeys from inhalational anthrax

Anthrax vaccine administered in combination with a short course of antibiotics completely protected nonhuman primates from inhalational anthrax, the most lethal form of the disease, according to scientists at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID).

In a collaborative study involving USAMRIID and the National Institute of Allergy and Infectious Diseases (NIAID), investigators demonstrated that postexposure vaccination can shorten the duration of antibiotic treatment required to protect against inhalational anthrax. The findings, which appear in this week's online edition of Proceedings of the National Academy of Sciences, could have important implications for public health management of anthrax bioterrorism events.

Anthrax is caused by the spore-forming bacterium Bacillus anthracis, and causes three types of disease--cutaneous, gastrointestinal, and inhalational--depending upon the route of exposure. Inhalational anthrax--the type likely to occur following a bioterrorist attack--is difficult to diagnose early, and despite antibiotic therapy, has a high fatality rate. In addition, because anthrax spores can remain in the body for extended periods, antibiotic treatment is typically recommended for 60 days or more following exposure.

As noted by the authors, following the 2001 anthrax attacks in the United States, approximately 10,000 people were offered 60 days of antibiotic therapy to prevent inhalational anthrax. Adverse events associated with this regimen--including diarrhea, nausea, vomiting, and dizziness--were commonly reported. More importantly, only about 44 percent of people completed the whole 60-day course. Thus, minimizing the duration of postexposure antibiotic treatment could be crucial to a successful defense against a large-scale anthrax attack.

In the study, two groups of rhesus macaques were exposed to very high amounts of anthrax spores by aerosol. Both groups were then given c
'"/>

Contact: Caree Vander Linden
Caree.Vanderlinden@us.army.mil
301-619-2285
US Army Medical Research Institute of Infectious Diseases
1-May-2006


Page: 1 2 3

Related biology news :

1. Vaccine trials inject hope into koalas future
2. Vaccine hope for malaria
3. Vaccine prevents prion disease in mice
4. Vaccine hope for sufferers of potentially fatal stomach bug
5. Vaccine to cope with viral diversity in HIV
6. PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine
7. U of S Vaccine and Infectious Disease Organization team discovers key step in flu virus replication
8. Vaccine-producing plant-factories
9. HPV Vaccine: Whats next
10. Vaccine shown effective against chancroid
11. Vaccine provides 100 percent protection against avian flu virus in animal study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/23/2019)... (PRWEB) , ... March 22, 2019 , ... ... Kit for Next Generation Sequencing (NGS) sample preparation. RhinoSeq employs a proprietary kit ... market. The five-tube kit is comprised of preformatted master mixes for a simple, ...
(Date:3/18/2019)... DIEGO (PRWEB) , ... March 18, 2019 , ... Periodontal ... to tooth loss, affects nearly 50% of the US population. Making this disease ... in a biofilm state, where the cells are enmeshed in a sticky extracellular material ...
(Date:3/18/2019)... COLUMBUS, Ohio and BERKELEY, Calif. (PRWEB) , ... ... ... company and Pivot Bio, the leader in microbial solutions announce today ... system for Pivot Bio PROVENTM, Pivot Bio’s breakthrough product for biologic nitrogen fixation ...
Breaking Biology News(10 mins):
(Date:4/10/2019)... ... April 10, 2019 , ... ... into multiple agreements to help companies advance their innovations to clinical testing ... from synthetic biology companies that are gene editing therapeutic cells for advanced ...
(Date:4/9/2019)... ... April 09, 2019 , ... Sonny Bar Lisa, or ... limb for approximately two months. After a series of diagnostics, an MRI was ... Sonny’s owner, Alison, researched the injury and found that VetStem Regenerative Cell Therapy ...
(Date:4/8/2019)... ... April 08, 2019 , ... US Capital Global Securities ... million preferred equity investment in the privately held pharmaceutical company, S1 Biopharma (“S1”). , ... is targeted at female hypoactive sexual dysfunction disorder and is ready to begin phase ...
(Date:4/4/2019)... ... 2019 , ... LeadingBiotech, an exclusive event series bringing biopharma ... Boston CEO conference to be held May 28-29, 2019 at Boston’s Four Seasons ... panels and discussions from past, present and future change-makers. , LeadingBiotech, ...
Breaking Biology Technology:
Cached News: